“We welcome CureVac’s decision to focus on promising technology for a second generation mRna vaccine we are developing together, since in preclinical tests it showed a strong improvement compared to the first generation vaccine candidate of CureVac (CVnCoV) “. Rino Rappuoli, Head of Vaccines R&D of Gsk, in the note in which the German CureVac announces the decision to withdraw CVnCoV from the current approval process underway at the European Medicines Agency Ema, to focus on the development of second-generation mRna vaccine candidates on which it is working in collaboration with the British Gsk.
The CureVac-Gsk alliance against Covid-19 is based on a strategic partnership related to messenger RNA technology, which the two companies launched in July 2020 with different objectives in the field of infectious diseases. A cooperation that has recently been extended – it is recalled in the note – with the deployment of additional resources by the two companies. The joint development activities concern second generation optimized mRna vaccines, which offer the potential to target several variants of the Sars-CoV-2 coronavirus, as well as prevent several diseases with a single injection and to offer improved forms of administration.